Lipanthyl S (Fenofibrate)

Fenofibrate activates the nuclear receptor PPAR‑α, which regulates genes involved in fatty‑acid oxidation and lipoprotein metabolism. This activation increases the breakdown of triglyceride‑rich particles, enhances lipoprotein lipase activity, and reduces hepatic production of VLDL, leading to lower serum triglycerides and modestly higher HDL‑cholesterol.

The appropriate dose of Lipanthyl S is determined by the prescribing clinician based on the individual patient's lipid profile, underlying health conditions, concomitant medications, and response to therapy. Dosage adjustments may be needed for renal or hepatic impairment, and the prescriber will follow local labeling and clinical guidelines.

Safety data for fenofibrate in pregnancy and lactation are limited. The drug should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To order Lipanthyl S, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Statins primarily reduce LDL‑cholesterol by inhibiting HMG‑CoA reductase, whereas fenofibrate (Lipanthyl S) mainly lowers triglycerides and modestly raises HDL‑cholesterol through PPAR‑α activation. Fenofibrate is often used as an adjunct to statins when triglyceride levels remain high despite statin therapy, offering a complementary mechanism of action.

Lipanthyl S should be stored at room temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, direct sunlight, and excessive heat. Do not store in the bathroom or near a kitchen sink where humidity is high.

Lipanthyl S is taken orally, usually as a tablet, with meals to improve absorption and reduce gastrointestinal discomfort. The exact timing and frequency are set by the prescriber, who may adjust the regimen based on the patient’s lipid levels and tolerance.

Serious adverse events linked to Lipanthyl S include rhabdomyolysis (especially when combined with statins), acute liver injury, pancreatitis, and severe allergic reactions such as anaphylaxis. Patients should be monitored for muscle pain, unexplained weakness, jaundice, or signs of an allergic response and seek medical attention promptly if they occur.

Lipanthyl S is contraindicated in patients with severe liver disease, active gallbladder disease or biliary obstruction, known hypersensitivity to fenofibrate or any excipients, and in individuals for whom the risks of therapy outweigh the benefits, such as certain pregnant or nursing women without a clear clinical indication.